These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10516371)

  • 21. Issues related to iron replacement in chronic kidney disease.
    Agarwal R; Warnock D
    Semin Nephrol; 2002 Nov; 22(6):479-87. PubMed ID: 12430092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
    Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
    Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parenteral iron supplementation in patients with end stage renal disease.
    Vogel SC
    ANNA J; 1998 Dec; 25(6):625-30. PubMed ID: 10188399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementing continuous quality improvement strategies for improving iron replacement in hemodialysis patients.
    Trenkle JA
    Nephrol Nurs J; 2001 Oct; 28(5):561-5. PubMed ID: 12143432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis.
    Susantitaphong P; Alqahtani F; Jaber BL
    Am J Nephrol; 2014; 39(2):130-41. PubMed ID: 24513913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron supplementation in renal anemia.
    Fishbane S
    Semin Nephrol; 2006 Jul; 26(4):319-24. PubMed ID: 16949471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Principles of iron therapy in hemodialysis patients].
    Basić-Jukić N; Kes P; Jurić I
    Acta Med Croatica; 2006 Dec; 60(5):457-62. PubMed ID: 17217102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous iron therapy in end-stage renal disease.
    Brewster UC
    Semin Dial; 2006; 19(4):285-90. PubMed ID: 16893405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxic effects of IV iron preparations in CKD patients.
    Vaziri ND
    Nephrol News Issues; 2014 Feb; 28(2):4-5. PubMed ID: 24649744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical practice guidelines for maintaining adequate iron status with intravenous iron dextran in hemodialysis patients.
    Peacock E; Lindenfeld SM
    ANNA J; 1999 Jun; 26(3):337-43. PubMed ID: 10633605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
    Gentil MA; Pérez-Valdivia MA; López-Mendoza M; Ortega F; Arias M; Gómez-Alamillo C; Campistol JM;
    Transplant Proc; 2008 Nov; 40(9):2922-4. PubMed ID: 19010148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients.
    Kaneko Y; Miyazaki S; Hirasawa Y; Gejyo F; Suzuki M
    Kidney Int; 2003 Mar; 63(3):1086-93. PubMed ID: 12631092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of renal anemia with iron in hemodialysis patients in General Hospital Bjelovar].
    Lovcić V; Vujić J; Basić-Jukić N; Janković RI; Kurtović I; Dzapo M; Lovcić P
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():45-8. PubMed ID: 23120815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The iron story: red smoke and magnetism?
    Wish JB
    Nephrol News Issues; 2014 Feb; 28(2):2-3. PubMed ID: 24649743
    [No Abstract]   [Full Text] [Related]  

  • 36. Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease.
    Varma R; Garrick R; McClung J; Frishman WH
    Cardiol Rev; 2005; 13(2):98-107. PubMed ID: 15705261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin.
    Weiss G; Meusburger E; Radacher G; Garimorth K; Neyer U; Mayer G
    Kidney Int; 2003 Aug; 64(2):572-8. PubMed ID: 12846752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing anemia using laboratory trend analysis. Case study of the anemic patient.
    Aiello J
    ANNA J; 1999 Aug; 26(4):430-3. PubMed ID: 10838975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of intravenous iron in hemodialysis patients.
    Li X; Kshirsagar AV; Brookhart MA
    Hemodial Int; 2017 Jun; 21 Suppl 1(Suppl 1):S93-S103. PubMed ID: 28370957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI.
    Eschbach JW
    Semin Nephrol; 2000 Jul; 20(4):320-9. PubMed ID: 10928333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.